Table 1.
Characteristics of 152 eligible patients with newly diagnosed DLBCL in the innovator and biosimilar rituximab groups
| Characteristic | Innovator rituximab | Biosimilar rituximab | P value |
|---|---|---|---|
| Total (N) | 60 | 92 | |
| Gender [n (%)] | |||
| Male | 46 (76) | 65 (70) | 0.414 |
| Female | 14 (24) | 27 (30) | |
| Median age at diagnosis [y (range)] | 52 (15–78) | 50 (20–76) | 0.443 |
| Elderly (> 60 years) [n (%)] | 17 (28) | 21 (23) | 0.443 |
| LDH(IU/L) > ULNa [n (%)] | 37 (62) | 81 (88) | 0.001 |
| Extra-nodal sites ≥ 2 [n (%)] | 2 (1) | 2 (2) | 0.225 |
| Bulk disease [n (%)] | 8 (13) | 20 (22) | 0.191 |
| Stage III/IV [n (%)] | 30 (50) | 49 (54) | 0.323 |
| R-IPIb [n (%)] | |||
| 0 | 14 (24) | 4 (5) | 0.001 |
| 1–2 | 24 (40) | 54 (58) | |
| 3–5 | 22 (36) | 34 (37) | |
aULN Upper limit of normal
bR-IPI Revised International Prognostic Index